Please note the ANZCTR will be unattended from 21/12/2018 until 08/01/2019. During this time no submissions or updates will be processed. Please ensure all trials are submitted/updated as soon as possible if you wish for them to be reviewed prior to the unattended period.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from

For full trial details, please see the original record at

Registration number
Ethics application status
Date submitted
Date registered
Date last updated

Titles & IDs
Public title
The Effect of Zoledronic Acid on Bone Density in Liver Transplant Patients
Scientific title
The Effect Of The Bisphosphonate, Zoledronic Acid, On Bone Density In Liver Transplant Patients – A Prospective, Randomised, Controlled Clinical Trial
Secondary ID [1] 0 0
CZOL446 AU02
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Osteoporosis 0 0
Liver Transplantation 0 0
Fractures 0 0
Condition category
Condition code
Musculoskeletal 0 0 0 0

Study type
Description of intervention(s) / exposure
Treatment: Drugs - zoledronic acid

Treatment: Drugs: zoledronic acid

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Primary outcome [1] 0 0
bone density
Timepoint [1] 0 0
Secondary outcome [1] 0 0
bone turnover markers
Timepoint [1] 0 0

Key inclusion criteria
- Greater than 17 years of age
Minimum age
17 Years
Maximum age
70 Years
Both males and females
Can healthy volunteers participate?
Key exclusion criteria
- Concurrent treatment, or within the past 12 months, with drugs known to affect bone

- Hypocalcemia

- Renal impairment (creatinine >1.5x ULN)

Study design
Purpose of the study
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?

Intervention assignment
Single group
Other design features
Phase 4
Type of endpoint(s)
Statistical methods / analysis

Recruitment status
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Date of last participant enrolment
Date of last data collection
Sample size
Accrual to date
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Sydney
Recruitment postcode(s) [1] 0 0
2050 - Sydney

Funding & Sponsors
Primary sponsor type
Royal Prince Alfred Hospital, Sydney, Australia
Other collaborator category [1] 0 0
Commercial sector/Industry
Name [1] 0 0
Address [1] 0 0
Country [1] 0 0

Ethics approval
Ethics application status

Brief summary
Following liver transplantation, rapid bone loss occurs, particularly within the first 6
months post-transplant. This may be associated with fractures, most notable vertebral. The
ability to assess osteoporosis therapies in this system may provide useful information for
osteoporosis management in general.


1. That treatment with the bisphosphonate, zoledronate, at the time of liver
transplantation and at 1 month post-transplantation will prevent the early
transplant-related bone loss (measured by bone densitometry and biochemical bone markers
at 3 months) seen in patients who are not treated with a bisphosphonate

2. That continuing treatment with zoledronate at 3 monthly intervals for a total duration
of 12 months will result in further improvements in bone density beyond that seen at 3

3. That calcium and vitamin D (vit D) supplementation of liver transplant patients does not
prevent marked bone loss following transplantation.
Trial website
Trial related presentations / publications
McDonald JA, Dunstan CR, Dilworth P, Sherbon K, Sheil AG, Evans RA, McCaughan GW. Bone loss after liver transplantation. Hepatology. 1991 Oct;14(4 Pt 1):613-9.
Public notes

Principal investigator
Name 0 0
Geoffrey McCaughan, PhD, MB BS
Address 0 0
Royal Prince Alfred Hospital, Sydney, Australia
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries

No data has been provided for results reporting
Summary results
Other publications